Ultragenyx to pay NIH 20% of PRV sale proceeds under deal with U.S. Department of Health
RARE•A SEC filing says Ultragenyx will pay the NIH 20% of proceeds from a PRV sale under a deal with the U.S. Department of Health.
1. Deal terms
Ultragenyx Pharmaceutical agreed to pay the NIH 20% of proceeds from a PRV sale under a deal with the U.S. Department of Health, according to a SEC filing.
